Preclinical studies at the Università degli studi di Roma Tor Vergata confirm that the drug candidate RCD405 has both airway dilation and anti-inflammatory effects. Thus, another piece is added to the development puzzle for the Lund-based company, which is aiming for the ever-growing COPD and asthma markets.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/05/new-results-confirmation-for-arcede-pharma/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/arcede-pharma/r/biostock--new-results-confirmation-for-arcede-pharma,c3975693

(c) 2024 Cision. All rights reserved., source Press Releases - English